Christopher Galletta - 02 Dec 2025 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Controller and Principal Accounting Officer
Signature
/s/ Christopher Galletta
Issuer symbol
TRVI
Transactions as of
02 Dec 2025
Net transactions value
+$2,159
Form type
4
Filing time
03 Dec 2025, 16:16:39 UTC
Previous filing
03 Jun 2025
Next filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Galletta Christopher Controller and Principal Accounting Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN /s/ Christopher Galletta 03 Dec 2025 0001486099

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $2,159 +4,225 +19% $0.5110 26,095 02 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -4,225 -21% $0.000000 15,775 02 Dec 2025 Common Stock 4,225 $0.5110 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 6,870 shares purchased through the Issuer's employee stock purchase plan.
F2 This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

Remarks:

Controller and Principal Accounting Officer